vs
Side-by-side financial comparison of Cingulate Inc. (CING) and HeartSciences Inc. (HSCS). Click either name above to swap in a different company.
Cingulate Inc. runs the higher net margin — 3639.3% vs -97179.4%, a 100818.6% gap on every dollar of revenue.
Cingulate Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for central nervous system disorders, including attention-deficit/hyperactivity disorder, anxiety and depression. It primarily operates in the U.S. market, focusing on advancing its proprietary precision drug delivery platform to improve patient outcomes across psychiatric and neurological care segments.
Meril Life Sciences is an Indian multinational medical device company, with headquarters in Vapi, Gujarat, India. It was founded in 2006 and is a part of the Bilakhia Group. The company is engaged in the manufacturing of vascular intervention devices, orthopedic implants, robotics, endosurgery, ENT products and in-vitro diagnostics. Meril Life Sciences operates in over 150 countries and has employed 10000 people, as of 2024.
CING vs HSCS — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $-136.9K | $2.4K |
| Net Profit | $-5.0M | $-2.4M |
| Gross Margin | — | 58.3% |
| Operating Margin | 3395.9% | -85713.2% |
| Net Margin | 3639.3% | -97179.4% |
| Revenue YoY | -3815.6% | — |
| Net Profit YoY | -54.3% | -12.9% |
| EPS (diluted) | $-1.09 | $-0.85 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.4K | ||
| Q3 25 | — | $1.9K | ||
| Q2 25 | $-136.9K | — | ||
| Q1 25 | $-96.8K | $0 | ||
| Q2 24 | $-3.5K | — | ||
| Q1 24 | $-24.3K | $14.7K | ||
| Q4 23 | — | $3.9K | ||
| Q2 23 | — | $0 |
| Q4 25 | — | $-2.4M | ||
| Q3 25 | — | $-2.1M | ||
| Q2 25 | $-5.0M | — | ||
| Q1 25 | $-3.9M | $-2.5M | ||
| Q2 24 | $-3.2M | — | ||
| Q1 24 | $-3.0M | $-1.6M | ||
| Q4 23 | — | $-1.7M | ||
| Q2 23 | — | $-1.6M |
| Q4 25 | — | 58.3% | ||
| Q3 25 | — | 60.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 69.0% | ||
| Q4 23 | — | 61.0% | ||
| Q2 23 | — | — |
| Q4 25 | — | -85713.2% | ||
| Q3 25 | — | -98637.8% | ||
| Q2 25 | 3395.9% | — | ||
| Q1 25 | 3829.2% | — | ||
| Q2 24 | 91683.7% | — | ||
| Q1 24 | 12152.6% | -10376.7% | ||
| Q4 23 | — | -40254.9% | ||
| Q2 23 | — | — |
| Q4 25 | — | -97179.4% | ||
| Q3 25 | — | -108157.6% | ||
| Q2 25 | 3639.3% | — | ||
| Q1 25 | 3980.7% | — | ||
| Q2 24 | 92375.9% | — | ||
| Q1 24 | 12252.6% | -11182.4% | ||
| Q4 23 | — | -44830.2% | ||
| Q2 23 | — | — |
| Q4 25 | — | $-0.85 | ||
| Q3 25 | — | $-1.58 | ||
| Q2 25 | $-1.09 | — | ||
| Q1 25 | $-1.04 | $-2.57 | ||
| Q2 24 | $-5.47 | — | ||
| Q1 24 | $-7.21 | $-3.01 | ||
| Q4 23 | — | $-15.92 | ||
| Q2 23 | — | $-79.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.9M | $2.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.5M | $4.2M |
| Total Assets | $13.5M | $6.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $2.8M | ||
| Q2 25 | $8.9M | — | ||
| Q1 25 | $9.5M | $2.6M | ||
| Q2 24 | $380.9K | — | ||
| Q1 24 | $1.1M | $7.1M | ||
| Q4 23 | — | $100.1K | ||
| Q2 23 | — | $1.7M |
| Q4 25 | — | $4.2M | ||
| Q3 25 | — | $3.1M | ||
| Q2 25 | $5.5M | — | ||
| Q1 25 | $5.9M | $1.8M | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | $3.2M | $8.6M | ||
| Q4 23 | — | $-1.6M | ||
| Q2 23 | — | $230.6K |
| Q4 25 | — | $6.0M | ||
| Q3 25 | — | $6.4M | ||
| Q2 25 | $13.5M | — | ||
| Q1 25 | $12.5M | $5.7M | ||
| Q2 24 | $5.1M | — | ||
| Q1 24 | $5.5M | $10.8M | ||
| Q4 23 | — | $2.4M | ||
| Q2 23 | — | $3.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $-2.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-2.3M | ||
| Q3 25 | — | $-2.0M | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $-4.6M | $-1.6M | ||
| Q2 24 | $-1.7M | — | ||
| Q1 24 | $-8.7M | $-2.1M | ||
| Q4 23 | — | $-988.2K | ||
| Q2 23 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-8.8M | $-2.1M | ||
| Q4 23 | — | $-990.1K | ||
| Q2 23 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | 51892.1% | — | ||
| Q1 24 | 36388.6% | -14352.1% | ||
| Q4 23 | — | -25388.2% | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q2 24 | -2076.8% | — | ||
| Q1 24 | -336.0% | 59.8% | ||
| Q4 23 | — | 50.1% | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
